Misonix brings Sonablate to Europe

Misonix has launched the Sonablate 500 prostate cancer treatment system in Western Europe, Eastern Europe, and Russia.

Sonablate 500 employs high-intensity focused ultrasound for the treatment of prostate cancer, enlarged prostate, and other prostatic tumors, according to the Farmingdale, NY-based vendor. Misonix has exclusive distribution rights for Sonablate 500, which is licensed from Focus Surgery of Indianapolis

By AuntMinnie.com staff writers
March 31, 2004

Related Reading

Misonix to distribute Sonablate 500 in Europe, March 2, 2004

Misonix continues gains in Q2, January 29, 2004

Misonix shows Q1 uptick, October 30, 2003

Misonix gets approvals for Sonablate 500, August 10, 2001

Misonix hires Berger as scientific and industrial VP, May 18, 2001

Copyright © 2004 AuntMinnie.com

Page 1 of 180
Next Page